CPIX
Cumberland Pharmaceuticals Inc. (CPIX) ESG Analysis Analysis (2026)
No material changes this month.
Environmental
R&D intensity at 16.1% of revenue suggests a comparatively science-led model, which can support lower resource intensity than peers with heavier manufacturing footprints.
Low debt-to-equity of 0.27 and negative net debt to EBITDA indicate limited balance-sheet pressure, reducing financing constraints on environmental compliance versus leveraged peers.
The provided metrics do not disclose emissions, energy use, or waste data, so environmental positioning cannot be confirmed as leading relative to peers.
High gross margin may reflect a less materials-intensive operating profile than peers, but the absence of direct environmental disclosures limits confidence in that advantage.
Social
R&D spending at 16.1% of revenue can support product quality and patient benefit, but peer-relative social strength remains hard to verify without workforce or access data.
Stock-based compensation at 1.4% of revenue suggests moderate reliance on equity incentives, which may align employee interests better than peers with heavier dilution.
No metrics are provided on safety, turnover, diversity, or community impact, leaving social risk assessment dependent on limited proxy indicators versus peers.
The capital structure appears conservative, which can support continuity and stakeholder stability, yet it does not by itself establish superior social performance.
Governance
Stock-based compensation at 1.4% of revenue is relatively restrained, indicating better capital discipline than peers that use equity more aggressively.
Debt-to-equity of 0.27 suggests prudent leverage management, which typically reduces governance pressure from creditors compared with more indebted peers.
Negative net debt to EBITDA implies net cash-like positioning, lowering refinancing risk and supporting board flexibility versus leveraged competitors.
The absence of board, audit, ownership, and controversy data prevents a top-tier governance assessment, despite the favorable capital-allocation signals.
Overall Score
CPIX screens as a stronger-than-average ESG profile versus peers, led by disciplined capital structure and moderate equity compensation, but limited disclosure prevents a higher score.
Score Driver: Conservative Leverage And Restrained Stock-Based Compensation Relative To Peers.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on Cumberland Pharmaceuticals Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.
